Journal of Neurology

, Volume 259, Issue 11, pp 2293–2298

Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy

  • Olivier Outteryck
  • Jean-Claude Ongagna
  • Alain Duhamel
  • Hélène Zéphir
  • Nicolas Collongues
  • Arnaud Lacour
  • Marie-Céline Fleury
  • Anne-Sophie Berteloot
  • Frédéric Blanc
  • Marianne Giroux
  • Patrick Vermersch
  • Jérôme de Sèze
Original Communication

DOI: 10.1007/s00415-012-6487-5

Cite this article as:
Outteryck, O., Ongagna, JC., Duhamel, A. et al. J Neurol (2012) 259: 2293. doi:10.1007/s00415-012-6487-5

Abstract

To measure the prevalence of JCV-specific antibodies in a French cohort of MS patients treated with natalizumab and to identify risk factor(s) of JCV seropositivity. Progressive multifocal leukoencephalopathy (PML) risk may be stratified by anti-JCV antibody status, duration of natalizumab therapy (≥24 months) and prior exposure to immunosuppressive (IS) drugs. No data are available in France on the prevalence of anti-JCV antibodies and distribution of PML risk factors in patients treated with natalizumab. Sera of 361 patients under natalizumab therapy in two MS centers were analyzed using a previously validated ELISA test. We studied different characteristics: demographic, ethnic, radiological, clinical, prior use of immunomodulatory (IM) or IS drugs and natalizumab exposure duration. The JCV seropositivity rate was 51 % for the whole cohort. Mean natalizumab exposure duration was 27.27 months ± 15.57 (mean ± SD), and prior use of IS drugs was observed in 15.24 % of patients. Twenty-three patients (6.4 %) presented the three PML risk factors. By multivariate analysis, presence of anti-JCV antibodies was significantly linked to age, North African origin and natalizumab exposure duration. Anti-JCV antibody prevalence was similar to previously published data. Anti-JCV antibody status was linked to age. We also suggested that anti-JCV antibody status could be linked to natalizumab exposure duration and ethnic characteristics.

Keywords

Multiple sclerosisNatalizumabJCVProgressive multiple leukoencephalopathy

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Olivier Outteryck
    • 1
  • Jean-Claude Ongagna
    • 2
  • Alain Duhamel
    • 3
  • Hélène Zéphir
    • 1
  • Nicolas Collongues
    • 2
  • Arnaud Lacour
    • 1
  • Marie-Céline Fleury
    • 2
  • Anne-Sophie Berteloot
    • 1
  • Frédéric Blanc
    • 2
  • Marianne Giroux
    • 1
  • Patrick Vermersch
    • 1
  • Jérôme de Sèze
    • 2
  1. 1.Department of NeurologyUniversity Hospital of Lille, Université Lille Nord de France, Hôpital Roger SalengroLille CedexFrance
  2. 2.Department of NeurologyUniversity Hospital of Strasbourg, Hôpital CivilStrasbourgFrance
  3. 3.Department of BiostatisticsCERIM EA2694Lille CedexFrance